The point you raise around alopecia is an interesting one. Especially around breast cancer. On the table above, Zantrene shows 83% of patients having zero to mild hair loss. Yet Dox had 74% of patients having moderate to severe hair loss. I imagine if those historical results are shared with women in the breast cancer trials, that alone would significantly improve our patient take-up. There’s an entire industry catering to cancer treatment wigs for women and anything we can do to help the emotional side of treatment would be a huge psychological win, let alone the obvious medical benefits of Zantrene
General Comments / Chat, page-7527
-
- There are more pages in this discussion • 3,608 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.85 |
Change
-0.090(4.64%) |
Mkt cap ! $315.1M |
Open | High | Low | Value | Volume |
$1.93 | $1.97 | $1.85 | $314.6K | 164.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 44 | $1.85 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.89 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 44 | 1.850 |
2 | 8804 | 1.840 |
3 | 6774 | 1.830 |
1 | 100 | 1.820 |
6 | 12943 | 1.800 |
Price($) | Vol. | No. |
---|---|---|
1.890 | 500 | 1 |
1.910 | 2941 | 1 |
1.940 | 148 | 1 |
1.950 | 1000 | 1 |
1.975 | 2000 | 1 |
Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |